MCED Testing Enters New Diagnostic Realms

Real-world performance data and trial results in symptomatic individuals continue to validate the promise of screening for multiple cancers with a single blood draw. However, some worry about the performance of GRAIL's commercially available multicancer early detection test in certain high-risk groups that were not the focus of early clinical development efforts.